Message #23 From:
Stock News Bot Date: September 6, 2006 06:18:00 AM
CLRI News Dutton Associates Announces Investment Opinion: Clearant Update for FDA Tissue Safety Task Force by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Sept. 6, 2006--Dutton Associates updates its coverage of Clearant Inc. (OTCBB:CLRI) for announcement of formation of the FDA tissue safety task force, maintaining its rating at Speculative Buy and a $3.00 price target. The research note issued September 1, 2006 by Dutton senior analyst Sally H. Wallick, CFA is available at www.duttonassociates.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
Clearant could benefit if a new Federal Food & Drug Administration (FDA) tissue safety task force results in increased demand for sterile tissue. The FDA said that it would establish a task force to evaluate how effectively its Good Tissue Practices (GTP) guidelines have been implemented and whether additional rules are needed to protect the public health. Creation of the task force follows two FDA investigations so far this year involving tainted tissue. We believe that more vigorous enforcement of the GTP guidelines by the FDA and/or more stringent safety requirements for tissue implants could be positive for Clearant, since its sterilization technology, the Clearant Process(R), currently is the only commercially available technology that inactivates all known infection-transmitting pathogens in biological products already sealed in their final packaging without affecting the functional integrity of the treated material. We reiterate our Speculative Buy rating on the stock. We consider the shares appropriate for aggressive investors willing to accept the above-average risk inherent in a small company in the early stages of commercializing a new technology.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $63,000 from the Company for 4 Research Reports with coverage commencing on 8/05/2005. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
